TScan Therapeutics’ (TCRX) “Buy” Rating Reaffirmed at Needham & Company LLC

Needham & Company LLC reiterated their buy rating on shares of TScan Therapeutics (NASDAQ:TCRX) in a research report released on Tuesday morning,Benzinga reports. The brokerage currently has a $11.00 price objective on the stock.

Several other brokerages also recently weighed in on TCRX. Wedbush reaffirmed an “outperform” rating and set a $10.00 price target on shares of TScan Therapeutics in a research report on Tuesday, November 5th. HC Wainwright reaffirmed a “buy” rating and set a $15.00 target price on shares of TScan Therapeutics in a report on Tuesday, August 13th. Five analysts have rated the stock with a buy rating, According to MarketBeat, the stock currently has a consensus rating of “Buy” and a consensus price target of $12.00.

TScan Therapeutics Price Performance

Shares of NASDAQ TCRX opened at $4.41 on Tuesday. TScan Therapeutics has a 52 week low of $3.73 and a 52 week high of $9.69. The company has a quick ratio of 7.77, a current ratio of 9.56 and a debt-to-equity ratio of 0.13. The firm has a market cap of $233.62 million, a P/E ratio of -4.16 and a beta of 0.79. The business’s 50 day moving average price is $5.31 and its 200 day moving average price is $6.49.

Insider Buying and Selling at TScan Therapeutics

In other TScan Therapeutics news, insider Zoran Zdraveski sold 164,686 shares of the stock in a transaction that occurred on Friday, August 23rd. The stock was sold at an average price of $5.78, for a total transaction of $951,885.08. Following the completion of the transaction, the insider now owns 4,716 shares of the company’s stock, valued at $27,258.48. This represents a 97.22 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, Director Barbara Klencke purchased 5,000 shares of the stock in a transaction dated Monday, August 26th. The stock was purchased at an average cost of $5.53 per share, for a total transaction of $27,650.00. Following the completion of the purchase, the director now directly owns 40,000 shares of the company’s stock, valued at approximately $221,200. The trade was a 14.29 % increase in their ownership of the stock. The disclosure for this purchase can be found here. Over the last three months, insiders have acquired 15,000 shares of company stock valued at $82,550. Company insiders own 2.76% of the company’s stock.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Dimensional Fund Advisors LP purchased a new position in shares of TScan Therapeutics in the second quarter worth about $70,000. SG Americas Securities LLC purchased a new position in TScan Therapeutics in the 3rd quarter worth approximately $78,000. The Manufacturers Life Insurance Company acquired a new position in shares of TScan Therapeutics during the 2nd quarter worth approximately $90,000. XTX Topco Ltd purchased a new stake in shares of TScan Therapeutics in the third quarter valued at approximately $112,000. Finally, MetLife Investment Management LLC increased its holdings in shares of TScan Therapeutics by 129.1% in the third quarter. MetLife Investment Management LLC now owns 23,363 shares of the company’s stock valued at $116,000 after purchasing an additional 13,164 shares during the last quarter. Hedge funds and other institutional investors own 82.83% of the company’s stock.

About TScan Therapeutics

TScan Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops T cell receptor-engineered T cell (TCR-T) therapies for the treatment of patients with cancer in the United States. The company's lead product candidates include TSC-100 and TSC-101 that is in Phase I clinical trial for the treatment of patients with hematologic malignancies to eliminate residual disease and prevent relapse after allogeneic hematopoietic cell transplantation.